Cerebrospinal Fluid Transcriptional Immune Pathways Linked to Survival in HIV-Associated Tuberculous Meningitis
Open Access
- 18 June 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e896-e907
Abstract
TB meningitis (TBM) has up to 50% mortality in people living with HIV. We investigated differences in cerebrospinal fluid (CSF) host immune responses associated with short-term mortality. We enrolled a prospective cohort of adults with definite, probable and possible HIV-related TBM in Kampala, Uganda. Metagenomic next-generation sequencing (mNGS) of bulk CSF RNA was used to detect co-infecting or alternate CNS pathogens and refine cohort diagnosis. Host transcriptomic profiles from the refined cohort were then compared between 14-day survivors and non-survivors. CSF mNGS reclassified or excluded 14% of participants based on pathogen detection, yielding 110 participants for transcriptomic analysis, of whom 23% (n=25) died within 14 days. More than 2000 genes were differentially expressed in the CSF based on 14-day mortality (adjusted p-value LCK, FYN, LAT), T-cell survival and differentiation (IL7, CD27, IL12RB1), B-cell receptor signaling (CD81, PLCG2, TNFRSF13C), cytotoxic lymphocyte and NK cell genes (KLRD1, ULBP1), TNF signaling, and class I MHC antigen processing pathways, while downregulating neutrophil chemoattractant CXCL1 and classical complement genes C4A and C4B. Unsupervised clustering identified a hypoinflammatory subgroup with significantly elevated mortality. Short-term TBM survival was associated with upregulation of adaptive immunity – including T-cell, B-cell, NK cell, and cytotoxic lymphocyte signaling – alongside TNF signaling and IFN-γ-driven class I MHC antigen processing pathways, with concurrent restraint of complement and neutrophil pathways. This supports investigation of targeted immunomodulatory agents that preserve protective responses while selectively dampening injurious innate pathways, rather than broad immunosuppression with corticosteroids.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI145437)
- National Institute of Allergy and Infectious Diseases (R01AI170158)
- Fogarty International Center (R01NS086312)
- Fogarty International Center (D43TW009343)
- UCSF Center for Tuberculosis (R25AI147375)
- UCSF Center for Tuberculosis (P30AI168440)
- Westridge Foundation
- American Academy of Neurology Clinical Research Training Scholarship
- Wellcome Trust (210772/Z/18/Z)
- University of California, San Francisco
- PBBR
- RRP IMIA
- Norges Idrettshøgskole (1S10OD028511-01)
This publication has 50 references indexed in Scilit:
- Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: A case seriesMed, 2022
- Tuberculosis endotypes to guide stratified host-directed therapyMed, 2021
- Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation studyThe Lancet Infectious Diseases, 2020
- The pathogenesis of tuberculous meningitisJournal of Leukocyte Biology, 2019
- Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort studyThe Lancet Infectious Diseases, 2018
- The GAIT translational control systemWIREs RNA, 2017
- Antibodies and tuberculosisTuberculosis, 2016
- Innate and Adaptive Interferons Suppress IL-1α and IL-1β Production by Distinct Pulmonary Myeloid Subsets during Mycobacterium tuberculosis InfectionImmunity, 2011
- IL-17 and Th17 cells in tuberculosisCytokine & Growth Factor Reviews, 2010
- Tuberculous meningitis: a uniform case definition for use in clinical researchThe Lancet Infectious Diseases, 2010